Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel Pharma: Q3 Earnings Showcase Robust Growth
Rigel Pharma is a profitable biotech with three FDA-approved drugs, experiencing accelerating revenue growth led by Tavalisse's strong performance. RIGL trades at a significant discount to biotech peers, despite a 186% YTD stock rise and robust 2025 sales guidance, making it a contrarian BUY. Continued momentum in Tavalisse and emerging growth from Rezlidhia position RIGL for potential outperformance, with additional upside from clinical pipeline catalysts.
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong Buy
Rigel (RIGL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. ( RIGL ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Raymond Furey - Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary Raul Rodriguez - President, CEO & Director David Santos - Executive VP & Chief Commercial Officer Lisa Rojkjaer - Executive VP & Chief Medical Officer Dean Schorno - Executive VP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Mohamad Amin Makarem - Jefferies LLC, Research Division Presentation Operator Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Third Quarter 2025.
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.7 per share a year ago.
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL)
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
Rigel Pharmaceuticals is a commercial-stage biotech growing revenue with three marketed drugs and a promising pipeline. RIGL's product sales grew 72% YoY in 1H FY2025, with diversification reducing reliance on TAVALISSE and GAVRETO showing strong adoption. On FY2025 revenue projections, Rigel trades at ~2.8x forward EV/sales; valuing the company in line with the sector median implies a share price of approximately $63.
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
